StockNews.com Upgrades Theravance Biopharma (NASDAQ:TBPH) to “Buy”

Theravance Biopharma (NASDAQ:TBPH) was upgraded by investment analysts at StockNews.com from a “hold” rating to a “buy” rating in a note issued to investors on Thursday.

Other analysts have also issued research reports about the company. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price objective on shares of Theravance Biopharma in a research note on Wednesday, May 29th. BTIG Research began coverage on Theravance Biopharma in a research note on Friday, April 12th. They set a “buy” rating and a $21.00 price objective on the stock.

Theravance Biopharma Trading Up 5.8 %

Shares of NASDAQ TBPH traded up $0.51 during trading on Thursday, reaching $9.33. The company had a trading volume of 534,330 shares, compared to its average volume of 378,323. Theravance Biopharma has a twelve month low of $8.13 and a twelve month high of $11.71. The stock has a 50-day moving average price of $8.83 and a two-hundred day moving average price of $9.20. The stock has a market capitalization of $453.72 million, a PE ratio of -10.85 and a beta of 0.25.

Theravance Biopharma (NASDAQ:TBPH) last posted its quarterly earnings data on Monday, May 13th. The biopharmaceutical company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.04. The business had revenue of $14.50 million for the quarter, compared to analyst estimates of $14.54 million. Theravance Biopharma had a negative return on equity of 18.97% and a negative net margin of 72.79%. On average, sell-side analysts predict that Theravance Biopharma will post -0.42 EPS for the current year.

Institutional Trading of Theravance Biopharma

A number of hedge funds have recently added to or reduced their stakes in the business. Jacobs Levy Equity Management Inc. boosted its stake in Theravance Biopharma by 41.6% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 557,971 shares of the biopharmaceutical company’s stock worth $5,005,000 after buying an additional 163,951 shares during the last quarter. Kennedy Capital Management LLC boosted its stake in Theravance Biopharma by 3.7% in the 1st quarter. Kennedy Capital Management LLC now owns 38,202 shares of the biopharmaceutical company’s stock worth $343,000 after buying an additional 1,359 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in shares of Theravance Biopharma by 7.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 49,475 shares of the biopharmaceutical company’s stock valued at $444,000 after purchasing an additional 3,532 shares in the last quarter. State Board of Administration of Florida Retirement System lifted its stake in shares of Theravance Biopharma by 28.2% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 22,671 shares of the biopharmaceutical company’s stock valued at $203,000 after purchasing an additional 4,990 shares in the last quarter. Finally, Russell Investments Group Ltd. lifted its stake in shares of Theravance Biopharma by 55.7% in the 1st quarter. Russell Investments Group Ltd. now owns 45,114 shares of the biopharmaceutical company’s stock valued at $405,000 after purchasing an additional 16,135 shares in the last quarter. 99.10% of the stock is owned by institutional investors and hedge funds.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.